FDA Approved Bixlenvo: Should You Switch From Your HIV Pill?
If you're stuck on three or more HIV pills a day because prior resistance closed off the existing single-tablet options, Bixlenvo is the first evidence-backed chance to collapse your regimen into one small daily tablet without losing viral suppression. If you're already undetectable on Biktarvy, the trial data don't show any advantage to switching.
Bixlenvo pairs bictegravir, the same integrase inhibitor in Biktarvy, with lenacapavir, a first-in-class HIV capsid inhibitor. The FDA approved it on August 27, 2026 for virologically suppressed adults switching from a stable regimen. In two phase 3 trials, people who switched stayed suppressed at essentially the same rate as those who stayed on their old regimens. Non-inferior, not superior. What "old regimen" meant in each trial is where the story lives.
What lenacapavir actually adds
Lenacapavir attacks a target no other HIV drug touches: the viral capsid, the protein shell that packages the virus's genetic material. By locking the capsid in a hyperstable state, it disrupts the virus at more than one stage, both nuclear entry early on and the assembly of new virions later. Every other approved HIV class goes after a single viral enzyme at one step. Integrase inhibitors, nucleoside and non-nucleoside reverse transcriptase inhibitors, and protease inhibitors all miss the capsid entirely.
That matters for one reason: none of the existing resistance pathways touches lenacapavir. Someone whose virus has learned to survive years of NRTIs still has a fully susceptible target here. Pair lenacapavir with bictegravir and even a heavily resistant virus faces two active drugs from two mechanisms it has never seen. That's why a workable single tablet is newly possible for people who were locked out of the existing options.
The trial for the people it was built for
ARTISTRY-1 enrolled the people this drug was designed for. Its 557 participants had a median of 28 years on HIV therapy, were taking a median of three pills a day, and two thirds carried resistance to older NRTIs. Two of every three were randomly assigned to switch to Bixlenvo; the rest stayed on their multi-pill regimens. At 48 weeks, about 1% of each group had detectable virus. No one on Bixlenvo developed new resistance to either drug. Reported treatment satisfaction rose after the switch, which is what you'd expect when three or four pills become one.
That's the finding that matters. For someone stable on a complex regimen only because their virus rules out the current single-tablet options, Bixlenvo held the line on suppression while cutting the daily count to one. Five deaths occurred in the Bixlenvo group over the trial; none was judged related to the study drug.
For people already on Biktarvy
ARTISTRY-2 answered the next question: what about the much larger group already doing well on Biktarvy, today's standard single-tablet regimen? Suppressed adults on Biktarvy were randomized to switch to Bixlenvo or stay put, in a double-blind design. At 48 weeks, viral suppression was essentially identical between arms, with roughly 1% in each having detectable virus. Drug-related side effects ran in the 10 to 12% range in both groups, with no drug-related serious adverse events and no emergent resistance. The most common reactions across trials were headache, nausea, and diarrhea, each in the low single digits.
That's what non-inferior means here: if you're already suppressed on Biktarvy, Bixlenvo doesn't do the same job better. It does the same job, in one smaller tablet (about 7 by 13 mm), at a somewhat higher reported list price (roughly $4,595 versus $4,216 for a 30-day supply). Simplicity, not efficacy.
Who this actually changes things for
| Current regimen | Evidence for switching | Likely benefit |
|---|---|---|
| Complex multi-tablet regimen, prior resistance | ARTISTRY-1: matched suppression, no new resistance, higher satisfaction | One small daily tablet instead of three or more |
| Already suppressed on Biktarvy | ARTISTRY-2: no better, no worse at 48 weeks | Slightly smaller pill; no efficacy gain |
| Treatment-naive adult starting HIV therapy | Not studied in this indication | Unknown; existing single-tablet regimens remain the standard |
| Taking dofetilide or a strong CYP3A inducer | Contraindicated | Not a candidate; do not switch |
Two hard stops, and what still isn't known
Bixlenvo can't be taken with dofetilide (a heart-rhythm drug) or with strong CYP3A inducers like rifampin, carbamazepine, phenytoin, or St. John's wort. Check those against your full medication list before any conversation about changing therapy.
The 48-week data are strong on their own terms. But they're 48-week data. Longer follow-up will show how durable suppression stays under real-world adherence and whether resistance stays as rare over years as it was over one. Data are also thinner in populations the trials underrepresented, including women and people with hepatitis B coinfection, and treatment guidelines haven't yet been updated to place Bixlenvo alongside existing preferred regimens. Bixlenvo's headline is size; its substance is mechanism. For the minority stuck on complex regimens, that mechanism turns a handful of pills into one small tablet without trading away suppression. For everyone already suppressed on a modern single-tablet regimen, the question to bring to your HIV clinician is which of those two situations describes you.